Pregnancy and antiphospholipid syndrome

Area of Science:

• Obstetrics and Gynecology
• Rheumatology
• Hematology

Background:

• Antiphospholipid syndrome (APS) is a significant risk factor for adverse pregnancy outcomes.
• Younger patients with systemic lupus erythematosus (SLE) and a history of thrombosis are particularly vulnerable to APS complications.
• Lupus anticoagulant (LAC) has been identified as a critical marker for predicting adverse pregnancy outcomes in APS patients.

Purpose of the Study:

• To highlight the risks of APS in pregnancy, especially for specific patient subgroups.
• To emphasize the predictive value of LAC for adverse pregnancy outcomes.
• To question the established efficacy of heparin prophylaxis and suggest the need for new therapeutic strategies.

Main Methods:

• Review of existing literature and clinical data on APS and pregnancy.
• Analysis of risk factors, including patient age, SLE, and prior thromboses.
• Evaluation of LAC as a predictor of pregnancy complications.
• Assessment of current prophylactic treatments like heparin.

Main Results:

• APS is strongly associated with adverse pregnancy outcomes.
• Younger patients with SLE and prior thromboses face heightened risks.
• LAC demonstrates the highest predictive accuracy for adverse pregnancy outcomes.
• The effectiveness of heparin in preventing poor outcomes warrants re-evaluation.

Conclusions:

• APS poses a significant threat to pregnancy, especially in high-risk individuals.
• LAC is a crucial diagnostic and prognostic tool in managing APS pregnancies.
• Current therapeutic strategies, including heparin, may require reassessment, and novel treatments are under investigation.